Novavax Inc vs SpaceX — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while SpaceX trades at $144.3 (market cap $1.76T). The key difference: SpaceX is far larger — about 1343.5× Novavax Inc's market cap. Which is the better fit depends on your goals.
| NVAX | SPCX | |
|---|---|---|
Market Cap | $1.31B | $1.76T |
Sector | Health | Technology |
52-Week High | $11.19 | $202.09 |
52-Week Low | $6.22 | $108.27 |
Enterprise Value | $889.30M | $1.70T |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →